This combination is now part of an ongoing Phase II clinical trial (https://clinicaltrials.gov/ct2/show/NCT03572387) to study combined 5-AZA and ATRA treatment on top of standard of care in recurrent prostate cancer patients based on rising prostate-specific antigen (PSA) only. The gene discussed is KLK3; the disease is Familial prostate cancer.